Samuraciclib for treatable basal pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug called samuraciclib in people with a specific type of pancreatic cancer that can be removed with surgery or is confined to the pancreas. The drug may help stop the cancer from growing, and this study aims to see if it is safe and effective before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of pancreatic cancer (called basal) that has not spread to other organs.
- You are 18 years or older.
- You are physically active and able to care for yourself (ECOG 0-1).
- Your blood counts and liver/kidney function are within normal limits.
- You have a biopsy sample taken within the last 3 months, or are willing to have a new one taken.
- You have not had radiation therapy for this cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
This trial tests whether a special MRI scan can help doctors better plan treatment for people with pancreatic cancer that is borderline able to be removed by surgery. The study will check how the tumor responds to initial treatment before surgery.
This study tailors standard chemotherapy for pancreatic cancer based on whether the tumor has a change in the SMAD4 gene. The goal is to see if a specific treatment plan works better for each gene type.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
Hear when a new Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.